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Abstract: Steroidal and adamantane aminoacridine derivatives were prepared 
and tested as both botulinum neurotoxin (BoNT) inhibitors and antimalarials. 
Steroid-bound acridines provided good potency against both the BoNT/A and 
BoNT/B light chains (LCs). The observed inhibition of the BoNT/B LC by ca. 
50 % is the highest attained inhibitory activity against this serotype by 
acridine-based compounds to date. With respect to the antimalarial activity, the 
adamantane acridines were the most potent derivatives (IC50 = 6–9 nM, SI > 326), 
indicating that an adamantyl group is a better carrier than a steroidal motif for 
this indication.  
Keywords: antiviral, BoNT/A; BoNT/B; antimalarial; aminoacridine. 
INTRODUCTION 
Botulinum neurotoxins (BoNTs),** secreted by the anaerobic, spore-forming 
bacterium Clostridium botulinum, are the most potent of known biological tox-
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** Abbreviations: BoNT, botulinum neurotoxin; SNARE, soluble N-ethylmaleimide-sen-
sitive factor attachment protein receptor; BoNT/A, botulinum neurotoxin serotype A; 
BoNT/A LC, BoNT/A light chain; SMNPIs, small molecule non-peptidic inhibitors; ACR, 
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-1,2-diamine; ACR3, N-(6-chloro-2-methoxy-9-anthryl)propane-1,3-diamine; ACR5, 
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ins.1,2 The proteolytic activities of these enzymes are responsible for the poten-
tially fatal disease botulism, which is commonly associated with food contami-
nation, wound infection, and colonizing infection in infants. BoNTs can be easily 
produced and disseminated,3 and therefore are listed as priority biological threat 
agents.4 On the other hand, when dosed locally in minute concentrations, BoNTs 
are used for the effective treatment of severe diseases.5 
There are seven known BoNT serotypes identified as A–G. Each cleaves a 
component of the SNARE complex, which mediates the transport of acetylcho-
line into neuromuscular junctions.6,7 BoNTs are secreted as holotoxins composed 
of a heavy chain (HC) and light chain (LC), which are connected by a disulfide 
bridge.8,9 The HC, which transports the LC into the neuronal cytosol via an aci-
dic endosome, is comprised of two ≈50 kDa domains. The C-terminal domain 
(HC), the ganglioside and protein receptor-binding domain, plays a role in bind-
ing to the cell membrane and internalization of a toxin into cholinergic neurons; 
the N-terminal domain (HN) facilitates the release of the LC from endosomes into 
the cytosol. The LC is a zinc-dependent metalloprotease that cleaves SNARE 
proteins, thereby inhibiting the formation of the SNARE complex. BoNT sero-
types A and E cleave SNAP-25 (synaptosomal-associated protein (25 kDa)),10 
serotypes B, D, F11 and G cleave VAMP (vesicle-associated membrane pro-
tein),12 and serotype C cleaves both SNAP-25 and syntaxin 1.13 Serotype A 
(BoNT/A) is the most potent of the seven serotypes. For example, it is 106-fold 
more potent than cobra toxin and 1011-fold more potent than cyanide,6 and its 
lethal dose is estimated to be between 1 and 5 ng kg–1 for humans.14 Moreover, 
the BoNT/A LC is longest acting of the LC serotypes in the neuronal cytosol.15  
Currently, there are no therapies available for the treatment of BoNT LC-
mediated paralysis post-neuronal intoxication, although several different appro-
aches are currently under development. Two of these approaches include anti-
body-based therapeutics and small molecule-based therapeutics.16 However, anti-
bodies cannot reverse the proteolytic effects of the toxins after the LC component 
has entered the neuronal cytosol.2 Hence, the development of small molecules 
that will effectively inhibit proteolytic activity of BoNT LC after post-neuronal 
intoxication is of special interest, with the BoNT/A LC being the main enzyme of 
study. At this time, one of the best known inhibitors of the BoNT/A LC is mpp-
RATKML, which consists of the oligopeptide RATKML covalently bonded to 
2-mercapto-3-phenylpropionyl (mpp) group (Ki = 330 nM).17 However, peptides 
are readily hydrolyzed by proteases, thus limiting their application in the therapy. 
                                                                                                                   
N-(6-chloro-2-methoxyacridin-9-yl)pentane-1,5-diamine; ACR6, N-(6-chloro-2-methoxy-
acridin-9-yl)hexane-1,6-diamine; CQR, chloroquine resistant strain; CQS, chloroquine 
susceptible strain; MDR, multi-drug resistant strain; BS, binding site; QA, quinacrine; 
CQ, chloroquine; MFQ, mefloquine; ART, artemisinin; EA, ethyl acetate; DCM, dichloro-
methane; PCC, pyridinium chlorochromate; TFA, trifluoroacetic acid. 
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For this reason, the development of small molecule inhibitors is crucial. To this 
end, many inhibitors of the BoNT/A LC have been reported,18 and are composed 
of compounds that competitively coordinate the catalytic zinc ion,19 as well as 
allosteric inhibitors.20 The most potent possess Ki values ranging from 0.1–10 
μM and include zinc (Zn2+) bidentate coordinating hydroxamic acid 1,21 2,5-
diphenyl-thiophene derivative 2,22 and diazachrysene 323 (Chart 1). 
In contrast to BoNT/A LC inhibitors, a paucity of small molecules that inhi-
bit the BoNT/B LC has been reported. These include isocoumarine 4,24 aryl- 
-phosphoramidic acid ICD 282125, bis-benzimidazole-5-carboximidamide 526 
(which bidentately coordinates the catalytic Zn ion of enzymes), and L-chicoric 
acid 6 (which is reported to bond to an exosite of the enzyme).27 In addition, it 
has been reported that the reducing agent TCEP (tris(2-carboxyethyl)phosphine 
hydrochloride) reduces the disulfide bond connecting the HC–LC bond of the 
enzyme both in vitro and in neuronal cells, and that it works prophylactically 
with a maximum activity at 1 mM.28 In this way, the LC cannot undergo endo-
cytosis, and therefore cannot cleave VAMP. 
It is well known that many 4-aminoquinoline antimalarials act as inhibitors 
of the BoNT/A LC.29,30 In contrast, little has been reported about the efficacy of 
acridine-based (ACR) compounds as BoNT inhibitors. However, it was found 
that quinacrine (QA, Chart 2), effectively prolonged the time of BoNT/A block-
ing of nerve-elicited muscle twitch in isolated mouse diaphragms.31 Furthermore, 
it was found that QA was four times more efficacious than CQ, with a muscle 
twitch protective index of 2.85 at 10 μM. 
Malaria* is a devastating disease and a global health problem. It is estimated 
to cause 300–500 million clinical cases and ca. one million deaths per annum.32 
The most successive drugs appeared to kill the parasite either by producing toxic 
free radicals33 or by blocking the polymerization of heme, as in the case of the 
4-amino-7-chloroquinolines (ACQs).34 The development of widespread drug-
resistance to CQ has resulted in an urgent need for new drug modalities, for 
example, synthetic peroxide antimalarials,35 as well as for the development of 
novel molecules that prevent heme polymerization.36  
Quinacrine was the first synthetic antimalarial used clinically that acts as a 
blood schizonticide, but later it was replaced with the more efficient CQ.37 How-
ever, due to the widespread development of CQ resistant (CQR) strains, there is 
renewed interest for evaluating acridine-based compounds as antimalarials. For 
example, N-sulfonamide derivatives, obtained from various simple 9-aminoacri-
dines, show high antimalarial activity against both CQS and CQR strains.38 They 
do not lose activity even when the amino group is stripped of its basic character, 
which is in contrast to most CQs or other quinoline or acridine derivatives.39 Qui- 
                                                                                                                   
* Malaria is caused by five Plasmodium species, P. falciparum, P. ovale, P. vivax, P. malariae 
and P. knowlesi, of which P. falciparum causing cerebral malaria is the major death threat. 
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nolizidinyl and quinolizidinyl-alkyl derivatives of 9-amino-6-chloro-2-methoxy-
acridine were almost 10 times more active than CQ against CQR (W2) strain, and 
were as active as CQ against the CQS (D10) strain;40 a series of 9-amino-
acridines showed high inhibitory potency.41 Most active derivatives have diami-
nopropylidene side chains and exert low nM activity (EC50 in range 1–4.1 nM). 
Similar to AQ antimalarials, 9-aminoacridines inhibit polymerization of 
hemozoin. In a β-hematin inhibitory assay (BHIA), it was found that ACR deri-
vatives formed complexes with hematin in a 3:2 molar ratio (hematin:drug).42 It 
was shown that the presence of 2-methoxy, 6-chloro substituents and an ionizable 
terminal amino group are essential for good antimalarial activity. It was also 
discovered that ACRs inhibit DNA topoisomerase II,39,43 parasite folate meta-
bolism44 and plasmepsin II.45 However, chimeric derivatives with ART46 or 
AQ,47 as well as bis-ACR derivatives,39,48 showed poor activities. 
In addition to their significant antimalarial activity, ACR-based compounds 
exhibit other biological activities, including nuclear localization signal (NLS)- 
-labeling agents for plasmid DNA,49 photocleavage reagents for DNA,50 anti-
leishmania agents51 and anti-prion compounds.52  
Previously, we reported on the inhibitory activities of steroidal 4-amino-
quinolines 7–9 and adamantyl-aminoquinolines (for example, 10) against the 
BoNT/A LC30 and as antimalarial agents53 were reported (Chart 2). Specifically, 
these derivatives provided a high degree of inhibition of BoNT/A metallopro-
tease, as well as significant inhibition of CQS and more important, CQR strains 
of P. falciparum. Herein, the synthesis and biological evaluation of new ACR 
derivatives possessing steroid and adamantane carrier component are presented. 
RESULTS AND DISCUSSION 
Synthesis 
The syntheses of the ACR derivatives examined in this study are provided in 
Scheme 1, and the corresponding structures are given in Chart 3. First, aminoalk- 
N
NH
Cl
OMe
NH2
N
NH
Cl
OMe
NH(  )n (  )n
CARRIER
16 - 24
i
N
Cl
Cl
OMe ii
11 12: TMACR2: n = 1
13: TMACR3: n = 2
14: TMACR5:  n = 4
15: TMACR6: n = 5 
i) diamine, ; 
ii) ketone, NaBH3CN/ MeOH/CH3CN, or NaBH4 / MeOH or NaBH4 / Ti(OPr
i)4 / EtOH, or NaB(OAc)3H / DCM  
Scheme 1. Synthesis of acridine derivatives 12–24. 
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Chart 3. Structures of examined derivatives 16–24. 
ylamino acridines 12–15 were obtained by the heating of 6,9-dichloro-2-meth-
oxyacridine 11 with neat diamines.50 The spectra of the isolated products were in 
agreement with literature data, and the compounds were used in the next reaction 
step without additional purification. Derivatives 16–24 were synthesized using 
procedures described earlier.30,53 The 3-keto steroidal derivative (7α,12α-diace-
toxy-3-oxo-5β-cholan-24-oate)54 was coupled with aminoalkylamino acridines 
12 and 13 to afford the corresponding 3α-and 3β-diastereomers (16–19). The 
crude reaction product obtained from 12 afforded diastereomers 16 and 17 via 
chromatographic separation. However, derivatives obtained from 13 were only 
partially separated to afford 18 containing ca. 20 % of 19, and the second fraction 
consisting of both isomers in a 1:1.5 ratio. The configuration at C(3) of the 
derivatives 16–19 was deduced from the respective 1H-NMR spectra. The cor-
responding H–C(3) atom of derivative 16 had a broad multiplet at 2.50–2.34 
ppm, while that of derivative 17 had a narrow signal at 2.93 ppm. Therefore, 16 
has an axial H–C(3) (in the β-orientation) and acridine substituent in an α-orien-
tation (α-isomer). Consequently, 17 is the β-isomer since it has Hα–C(3) and the 
acridine substituent in the β-orientation. Based on the above correlations, it was 
possible to establish the approximate composition of mixtures obtained from par-
tially separated isomers 18 and 19. Steroidal alcohol 3α,7α,12α-triacetoxy-5β- 
-cholan-24-ol was oxidized to the corresponding aldehyde,30 which was further 
coupled to 12 and 13 to give the corresponding steroidal acridine derivatives 20 
and 21. Following the general approach, 2-(adamantyl)ethanal53 gave the ada-
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mantyl–acridine derivatives 22 and 23, and the benzaldehyde afforded N-benzyl 
acridine 24. The structures of all synthesized compounds were confirmed by 
spectral and analytical techniques, with all details given in the Supplementary 
material to this paper. 
Inhibition of BoNT/A LC 
The inhibitory efficacies of synthesized derivatives 16–21 and 24 at 20 μM 
concentration were obtained using a well-established HPLC-based assay for 
BoNT/A LC inhibition.55 These data are presented in Table I. The activities of 
corresponding aminoquinoline derivatives 7–9 were established previously,30 
and are provided for comparison. In this study, the inhibitory effects of CQ were 
also examined. It exhibited only marginal inhibition and thus clearly emphasized 
the necessity of the cholic acid component for superior inhibitory activity. 
TABLE I. In vitro inhibitory activities (%, at 20 μM concentration) of the tested compounds 
against BoNT/A LC and BoNT/B LC; N.T. – not tested 
Compound BoNT/A-LC BoNT/B-LC 
NSC 240898 81.43 77.38 
16 58.34 57.03 
17 58.25 52.04 
18 77.04 47.40 
19 59.38 48.10 
20 15.07 31.94 
21 61.25 33.63 
24 5.82 N.T. 
12 42 N.T. 
13 20 N.T. 
14 8 N.T. 
15 10 N.T. 
7a 74 N.T. 
8a 47.22 N.T. 
9a 56.26 N.T. 
CQb 6.51 N.T. 
MQc 28.06 N.T. 
aResults published earlier;31 btested as diphosphate salt; ctested as HCl salt 
The results given in Table I indicate that 9-aminoacridine derivatives 
coupled to cholic acid derivative as the carrier exhibited moderate to good acti-
vities against the BoNT/A LC, with potencies ranging from 58 to 77 % inhi-
bition. The exception is derivative 20, which provided only 15 % inhibition. The 
most active derivative was compound 18, which contains the acridine moiety in 
the β-orientation. However, the results obtained for derivatives 18 and 19 are not 
so easily interpretable, since both samples were mixtures of diastereomers: 18 
contained ≈20 % of the α-isomer, and 19 was a mixture of both isomers in 1:1.5 
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α:β ratio. Nevertheless, from the obtained results, it is plausible to assume that 
the pure β-isomer would have higher activity versus the pure α-isomer (since the 
former sample showed 20 % higher potency – 18 77.04 % inhibition vs. 19 59.38 % 
inhibition). 
The compounds incorporating acridine 12, i.e., 16 and 17, were equally 
potent, suggesting that the configuration at position C(3), in this instance, is not 
crucial for BoNT/A LC inhibition. Comparison of the inhibitory activities for 
steroidal acridines with the corresponding data for steroidal aminoquinolines 7–9 
indicates that these compounds expressed approximately the same level of inhi-
bitory capacity. This suggests that both acridine and quinoline moieties within 
the small molecule inhibitors engage in similar types of interactions with the 
active site of the BoNT LC metalloprotease. However, more reliable correlations 
will be made on pure isomers after measuring the corresponding Ki values.  
The simple 9-aminoacridines 12–15 exhibited poor inhibitory activity (8–20 % 
inhibition) with 12 being an exception (42 % inhibition). In addition, the results 
showed that elongation of the aminoalkyl chain leads to decreased activity for 
this class of inhibitor. The low activities of 9-aminoacridines 12–15 clearly indi-
cate that for good inhibitory activity, a carrier is necessary in order to enable 
additional interactions within the active site of a metalloprotease. The poor acti-
vity of N-benzyl derivative 24 further supports this observation.  
Derivatives 16–21 were also tested for inhibition of BoNT/B LC, giving rise 
to some of the most potent inhibitors of this serotype reported to date (Table I). 
The results indicate that steroidal C(3) derivatives are slightly more active in 
comparison to C(24) derivatives. Moreover, the results showed no differences 
between the stereoisomers, i.e., the Hβ–C(3) isomers exhibited the same level of 
activity as the Hα–C(3) isomers. The most active derivative was 16, which pro-
vides 57 % inhibition at 20 μM concentration.  
As steroidal 9-aminoacridines inhibited Zn proteases BoNT/A and B LCs, 
the next step was to examine the activity of synthesized derivatives against a 
sampling of human metalloprotease – to evaluate selectivity. The four derivatives 
16–19 were tested at 20 μM concentration against human metalloprotease ther-
molysin, serine protease trypsin, and cysteine protease papain. The results are 
given in Table II. The data indicate that the compounds are poor inhibitors of 
generic human proteases. The exception was derivative 18, which meaningfully 
inhibited papain. Nevertheless, in general, it could be concluded that these deri-
vatives selectivity inhibit BoNT LC metalloproteases (as opposed to human pro-
teases). In addition, the low activities of the compounds against the Zn-dependent 
protease thermolysin indicates the inhibitory potencies against BoNT LCs were 
not the result of general preferences for interaction with the Zn ion, but that addi-
tional specific interactions with the enzymes were involved. 
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TABLE II. Inhibitory activities (%,at 20 μM concentration) of ACR SMNPIs against human 
proteases; A: trypsin; B: thermolysin; C: papain 
N
H
NH2
NH
O
NH
NH2NSC 240898
 
Compound A B C 
NSC 240898  52.07 8.53 –11.78 
16 12.36 13.98 5.19 
17 17.24 15.42 20.76 
18 22.94 22.37 78.54 
19 7.48 12.68 –7.85 
Antimalarial activity 
It was previously shown that aminoquinoline SMNPIs exerted both BoNT 
inhibiting effects and were simultaneously excellent antimalarials.30,53 Based on 
this observation, acridine derivatives were elected for screening against three P. 
falciparum strains: D6 (a CQ and MFQ susceptible strain), W2 (a CQ-resistant, 
susceptible to MFQ strain), and TM91C235 (Thailand), a multi-drug-resistant 
strain, using a well-established protocol.55 The gathered in vitro antimalarial acti-
vities (Table III) show that all tested derivatives had significantly better activities 
than CQ against the CQR strain W2 (16–53 times) and the multi-drug resistant 
TM91C235 strain (2–24 times). Against the CQS strain D6, the steroidal deriva-
tives were less active than CQ; however, the other derivatives were as active as 
CQ. The steroidal acridines 20 and 21 were less active in comparison to 7 against 
all the tested strains. However, at the same time, the adamantyl derivatives 22 
and 23 were more active when compared to 10 against the CQR W2 and the 
multi-drug-resistant TM91C235 strains. Importantly, all the new derivatives were 
significantly more active than N-sulfonamides,38 9-amino-polyamide acridines,39 
aminoalkylamino acridines,42 and had activities to those of quinolizidinyl and 
quinolizidinylalkyl derivatives, which are the second best known acridine anti-
malarials.40 The most active of the derivatives was 22, with IC50(W2) = 8.6 nM, 
IC50(D6) = 9.3 nM and IC50(TM91C235) = 5.8 nM. Its in vitro activity is com-
parable to that of artemisinin (Table III). In addition, compound 22 had similar 
activity to those of the most potent diaminopropylidene-aminoacridine deriva-
tives described in the literature.41 
It should be emphasized that steroidal/adamantane carriers of the 9-amino-
alkylamino acridine moiety had significantly improved antimalarial activities. 
Comparatively, simple acridines such as 12 and 15 showed much lower anti-
malarial activity against the CQR W2 strain versus new derivatives (12 (IC50 = 
= 250 nM) and 15 (IC50 = 180 nM)).42 Thus, the attachment of these simple 
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ACRs to either cholic acid or the adamantyl moiety significantly increased 
antimalarial activity against CQR strains. The same trend was observed against 
the CQS strain. The results reported herein indicate that steroidal and adamantyl 
acridines are highly effective antimalarials. 
TABLE III. In vitro IC50 antimalarial activities (nM) and cytotoxicity of the compounds tested 
against P. falciparum strains; N.D. – not determined 
Compd. W2a D6b TM91C235c RId HEPG2 SIe 
20 23.8 41.5 51.8 1.25 / 0.57 4281 180 / 103 / 83 
21 23.3 39.0 53.0 1.36 / 0.60 1030 44 / 26 / 19 
22 8.6 9.3 5.8 0.62 / 0.92 >3030 >352 / >326 / >522 
23 11.2 15.7 12.2 0.78 / 0.71 3261 291 / 208 / 267 
24 28.0 17.9 15.6 0.56 / 1.56 1183 42 / 66 / 76 
7f 11.4 16.9 27.7 1.64 / 0.67 N.D. – 
10g 15.66 8.59 17.76    
12 250h N.D. N.D. – N.D. – 
15 180h N.D. N.D. – N.D. – 
CQ 456.20 12.27 138.82 23.17 / 43.32 N.D. – 
MFQ 4.93 15.70 36.50 3.43 / 0.39 N.D. – 
ARTi 6.70 9.00 13.40 1.36 / 0.90 N.D. – 
aP. falciparum Indochina W2 clone; bP. falciparum African D6 clone; cP. falciparum multi-drug resistant 
TM91C235 strain (Thailand); dresistance index, defined as the ratio of the IC50 for the resistant versus sensitive 
strain, TM91C235/D6 and W2/D6, respectively; eselectivity index, defined as the ratio of the IC50 for 
HepG2/W2, HepG2/D6 and HepG2/ TM91C235, respectively; fresults published earlier;30 gresults published 
earlier;53 hresults taken from literature;42 iaverage of more than eight replicates 
The toxicities of the new derivatives were estimated using the human liver 
carcinoma cell line HEPG2, and the results are given in Table III. The HEPG2 
cell line is frequently used for cytotoxicity examination of xenobiotics, since this 
cell line has low levels of CYP450 enzymatic activities and possible toxic effects 
are the result of particular molecules and not metabolites.56 In addition, since all 
xenobiotics pass through the liver, it is essential to know if they provide heapto-
toxic side effects. In this study, it was found that steroidal derivative 20, con-
taining aminoacridine part 12, was the least cytotoxic of the series, possessing an 
IC50 = 4281 nM. However, the adamantyl derivatives had a much better selec-
tivity index (SI) than the other antimalarials. Thus, 22 has SI values 352/326/522 
vs. 180/103/83 for 20, and thus have a higher therapeutic potential. It was also 
observed that elongation of aminoalkylamino chains by only one methylene 
group in 21 significantly increased cytotoxicity when compared to 20. 
EXPERIMENTAL 
Melting points were determined on a Boetius PMHK or a Mel-Temp apparatus and were 
not corrected. IR spectra were recorded on a Perkin-Elmer spectrophotometer FT-IR 1725X. 
NMR spectra were recorded on Varian Gemini-200, Varian XL-300, and Bruker AM-250 
spectrometers in the indicated solvent using TMS as an internal standard. Chemical shifts are 
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recorded in parts per million (ppm), and coupling constants J are expressed in Hz. ESI-MS 
spectra were recorded on an Agilent Technologies 6210 Time-Of-Flight LC-MS instrument in 
positive ion mode with CH3CN/H2O–0.2 % HCOOH as eluent. The samples were dissolved in 
CH3CN or MeOH (HPLC grade purity). The elemental analysis was performed on the Vario 
EL III – C, H, N, S/O elemental analyzer (Elementar Analysensysteme GmbH, Hanau, Ger-
many). Thin-layer chromatography (TLC) was performed on pre-coated Merck silica gel 60 
F254 and RP-18 F254 plates. For column chromatography, Lobar LichroPrep Si 60 (40–63 µm), 
RP-18 (40–63 µm) columns coupled to a Waters RI 401 detector were used, Biotage SP1 
system with UV detector. 
Methyl 7α,12α-diacetoxy-3α-{N-{2-[(6-chloro-2-methoxyacridin-9-yl)amino]ethyl}amino}- 
-5β--cholan-24-oate (16) and methyl 7α,12α-diacetoxy-3β-(N-{2-[(6-chloro-2-methoxy-
acridin-9--yl)amino] ethyl}amino)-5β-cholan-24-oate (17) 
To a solution of methyl 7α,12α-diacetoxy-3-oxo-5β-cholan-24-oate (300 mg, 0.59 mmol) 
in CH3CN (6.0 mL), 12 (357.9 mg, 1.19 mmol) in MeOH (3 mL) was added, and after stirring 
for 30 min at r.t., NaBH3CN (48.39 mg, 0.77 mmol) was added in one portion. The resulting 
mixture was further stirred for 2 h at r.t., followed by the addition of glac. AcOH (4 drops) 
and stirring was continued until TLC indicated the consumption of all starting ketone (ca. 1 
h). The reaction was quenched with Et3N, the solvents were evaporated to dryness, and after 
chromatographic purification (dry-flash, SiO2, gradient EA  EA/MeOH/NH3; Lobar RP-18, 
eluent MeOH/H2O = 9:1; Biotage flash SP, gradient EA/Hex = 6:4  EA/Hex = 9:1) 16 (45.0 
mg) and 17 (40 mg) were isolated (9.6 and 8.5 % yield, respectively). 
Methyl 7α,12α-diacetoxy-3β-(N-{3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl}amino)- 
-5β-cholan-24-oate (18) and methyl 7α,12α-diacetoxy-3α-(N-{3-[(6-chloro-2-methoxyacridin- 
-9-yl)amino]propyl}amino)-5β-cholan-24-oate (19) 
To a solution of methyl 7α,12α-diacetoxy-3-oxo-5β-cholan-24-oate (500 mg, 0.99 mmol) 
in CH3CN (9.5 mL), 13 (124.3 mg, 0.39 mmol) in MeOH (5 mL) was added, and after stirring 
for 30 min at r.t., NaBH3CN (82.8 mg, 1.32 mmol) was added in one portion. The resulting 
mixture was stirred for 2 h at r.t. followed by the addition of glac. AcOH (4 drops) and stirring 
was continued until TLC indicated the consumption of all starting ketone. The reaction was 
quenched with Et3N, the solvents were evaporated to dryness and after chromatographic 
purification (dry-flash, SiO2, gradient EA  EA/MeOH/NH3; Lobar RP-18, eluent MeOH/  
/H2O = 9:1; Biotage flash SP, gradient EA/Hex = 6:4  EA/Hex = 9:1) 18 and 19 were 
isolated (120.0 mg, 15 % and 90 mg, 11 %, respectively). 18 contained ca. 20 % of 3α-isomer 
19 and 19 was a mixture of a ca. 1:1.5 ratio of the β- and α-isomers. 
3α,7α,12α-Triacetoxy-24-{N-{2-[(6-chloro-2-methoxyacridin-9-yl)amino]ethyl}amino}-5β- 
-cholan (20) 
The alcohol 3α,7α,12α-triacetoxy-5β-cholan-24-ol (540 mg, 1.04 mmol) was dissolved 
in DCM (50 mL), PCC (185 mg, 1.56 mmol) was added and the mixture was stirred at r.t. for 
3.5 h. The reaction mixture was filtered through a short SiO2 column (eluent CH2Cl2/EA = 
= 95/5). Obtained crude aldehyde (500 mg) was dissolved in MeOH (10.0 mL), followed by 
12 (290 mg, 0.96 mmol) and mixture was stirred at r.t. After 12 h, NaBH4 (73 mg, 1.92 mmol) 
was added in one portion and stirring was continued at r.t. for 2 h. The solvent was evaporated 
to dryness and after chromatographic purification (dry-flash, SiO2, eluent EA/MeOH = 8/2), 
the desired product was isolated as an orange solid. Yield: 325 mg (42 %).  
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3α-7α,12α-Triacetoxy-24-{N-{3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl}amino}-5β- 
-cholan (21) 
The alcohol 3α,7α,12α-triacetoxy-5β-cholan-24-ol (540 mg, 1.04 mmol) was dissolved 
in DCM (50 mL), PCC (185 mg, 1.56 mmol) was added and the mixture was stirred at r.t. for 
3.5 h. The reaction mixture was filtered through a short SiO2 column (eluent CH2Cl2/EA = 
= 95/5). The obtained crude aldehyde (500 mg) was dissolved in MeOH (10.0 mL) followed 
by 13 (303 mg, 0.96 mmol), and the mixture was stirred at r.t. After 12 h, NaBH4 (73 mg, 1.92 
mmol) was added in one portion and stirring was continued at r.t. for 2 h. The solvent was 
evaporated to dryness and after chromatographic purification (dry-flash, SiO2, eluent EA/  
/MeOH = 8/2), product was isolated as an orange solid. Yield 230 mg (29 %).  
N-[2-(1-Adamantyl)ethyl]-N'-(6-chloro-2-methoxyacridin-9-yl)ethane-1,2-diamine (22) 
Into stirred mixture of 2-(1-adamantyl)acetaldehyde (140 mg, 0.86 mmol) and 12 (260 
mg, 0.86 mmol) in abs. EtOH (10 mL), Ti(OPri)4 (381 µL, 1.29 mmol) was added dropwise. 
After stirring for 1 h at r.t., NaBH4 (65 mg, 1.72 mmol) was added in one portion and when all 
the aldehyde had been consumed, the reaction was quenched with 0.1 M NaOH (10mL). The 
reaction mixture was extracted with CH2Cl2 (3×30 mL), the combined organic layers were 
washed with brine and dried over anh. Na2SO4. The solvent was removed under reduced pres-
sure and the crude product was purified by dry-flash chromatography (SiO2, eluent hexane/EA =  
= 1/1). Yield 40 mg (10 %).  
N-[2-(1-Adamantyl)ethyl]-N'-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-diamine (23) 
According to the procedure described for 22, 2-(1-adamantyl)acetaldehyde (140 mg, 0.86 
mmol) was transformed into 23 using 13 (271 mg, 0.86 mmol). The product was isolated after 
dry-flash chromatography (SiO2, eluent EA/MeOH = 8/2). Brown–orange amorphous solid. 
Yield: 190 mg (46 %).  
N-Benzyl-N'-(6-chloro-2-methoxyacridin-9-yl)ethane-1,2-diamine (24) 
To a stirred mixture of benzaldehyde (100 µL, 0.98 mmol) and 12 (312.0 mg, 1.03 
mmol) in CH2Cl2 (15 mL), NaB(OAc)3H (313.0 mg, 1.47 mmol) was added. After stirring for 
20 h at r.t., the reaction was quenched with 1 M NaOH (10 mL). The mixture was extracted 
with CH2Cl2 (3×30 mL), the combined organic layers were washed with brine and dried over 
anh. Na2SO4. The solvent was removed under reduced pressure and the crude product was 
purified by dry-flash chromatography (SiO2, eluent EA/MeOH = 95/5). Yield 230.0 mg (60 %).  
N-(6-Chloro-2-methoxyacridin-9-yl)ethane-1,2-diamine (12)57  
A solution of 6,9-dichloro-2-methoxyacridine 11 (600 mg, 2.15 mmol) in 1,2-diamino-
ethane (10 mL, 140 mmol) was stirred at 70 °C under an Ar atmosphere. After 1 h, the mix-
ture was poured into ice cold water, the powder was filtered and dried under reduce pressure. 
The product was obtained as a yellow powder and used in the next reaction step without 
further purification. Yield 580 mg (89 %). 
N-(6-Chloro-2-methoxy-acridin-9-yl)propane-1,3-diamine (13)57 
According to procedure described for 12, 6,9-dichloro-2-methoxyacridine (1 g, 3.59 
mmol) was transformed into 13 using 1,3-diaminopropane (20 mL, 232 mmol). The product 
was obtained as a yellow powder and used in the next reaction step without further puri-
fication. Yield 1.08 mg (95 %). 
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N-(6-Chloro-2-methoxyacridin-9-yl)pentane-1,5-diamine (14)49 
According to procedure described for 12 6,9-dichloro-2-methoxyacridine (500 mg, 1.79 
mmol) was transformed into 14 using 1,5-diaminopentane (13 mL, 11.3 g) at 80 °C. The 
product was obtained as yellow powder and used in next reaction step without further puri-
fication.  
N-(6-Chloro-2-methoxyacridin-9-yl)hexane-1,6-diamine (15)39  
According to procedure described for 12 6,9-dichloro-2-methoxyacridine (1g, 3.59 
mmol) was transformed in 15 using 1,6-diaminohexane (23 g, 197.9 mmol) at 90 °C. Product 
was obtained as yellow powder and used in next reaction step without further purification.  
In vitro BoNT LC metalloprotease activity 
Determination of BoNT/A LC percent inhibition by SMNPIs was performed as 
previously described.55  
For BoNT/B LC percent inhibition, the HTS-assay utilizes a commercially available 
fluorogenic substrate from List Biological Laboratories (Campbell, CA). Briefly, a multi-
channel pipette was used to add fluorescent substrate (final concentration 20 µM) and small 
molecules (final concentration 20 µM) to a 96 well microplate. The reactions were initiated by 
adding recombinant BoNT/B LC (final concentration 40 nM) to each well. All reactions were 
conducted in a buffered solution consisting of 40 mM Hepes pH 7.2, 1 mM DTT and 100 µM 
ZnCl2. The change in fluorescence intensity over time was continuously monitored in each 
well using a 96 well plate fluorimeter (Saphire 2, Tecan, Männedorf, Switzerland). The assays 
were run at 37 °C, quenched by the addition of TFA, and analyzed using reverse-phase HPLC. 
Potential SMNPIs of the BoNT B LC were identified by comparing the reaction velocities 
(change in fluorescence intensity over time) of samples assayed in the presence of compounds 
versus control samples.  
In vitro antimalarial activity and toxicity 
The in vitro antimalarial drug susceptibility and toxicity screening were realized at the 
Walter Reed Army Institute of Research.23 
CONCLUSIONS 
Aminoacridine derivatives possessing adamantane and steroid carriers were 
prepared and tested for BoNT/A LC, BoNT/B LC, and antimalarial activity. 
Acridines with the cholic acid-derived carrier showed good potency against both 
the BoNT/A LC and BoNT/B LC. The inhibition of the BoNT/B LC by ca. 50 % 
is the highest inhibitory activity of any acridine reported to date. The antimalarial 
potency of adamantane acridines (IC50 in range 6–9 nM), combined with their 
low potencies (IC50 ca. 3000 nM) is a good starting point for further research in 
this area. 
SUPPLEMENTARY MATERIAL 
Spectral and analytical data of all the synthesized compounds are available electronically 
at http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
НОВИ ДЕРИВАТИ 9-АМИНОАКРИДИНА КАО ИНХИБИТОРИ БОТУЛИНУМ 
НЕУРОТОКСИНА И P. falciparum ПАРАЗИТА МАЛАРИЈЕ  
МИКЛОШ ТОТ1, ДЕЈАН М. ОПСЕНИЦА2, МИЛЕНА МИТРИЋ1, JAMES C. BURNETT3, LAURA GOMBA4, 
SINA BAVARI
5 и БОГДАН А. ШОЛАЈА1 
1Хемијски факултет, Универзитет у Београду, Студентски трг 16, п. пр. 51, 11158 Београд, 
2Институт за хемију, технологију и металургију, Његошева 12, 11000 Београд, 3SAIC-Frederick, Inc., 
Frederick National Laboratory for Cancer Research, P. O. Box B, Frederick, MD 21702, USA, 4United States 
Army Medical Research Institute of Infectious Diseases, Department of Bacteriology, 1425 Porter Street, 
Frederick, MD 21702, USA и 5United States Army Medical Research Institute of Infectious Diseases, Fort 
Detrick, 1425 Porter Street, Frederick, MD 21702, USA 
Синтетисани су деривати стероидних и адамантил-акридина и испитана је њихова 
инхибиторна активност према ботулинум неуротоксинима (BoNT) и паразиту маларије. 
Стероидни акридини показују добру инхибицију према кратком низу (LCs) BoNT/A и 
BoNT/B. Остварена инхибиција BoNT/B LC од око 50 % је највша постигнута вредност 
акридинских деривата према овом серотипу. Адамантил–акридински деривати су пока-
зали највећу антималаријску активност (IC50 у опсегу 6–9 nM, SI > 326), показујући да је 
адамантил-група бољи носач фармакофоре у поређењу са стероидним, према овој инди-
кацији. 
(Примљено 24. септембра, ревидирано 20. октобра 2013) 
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